The US Food and Drug Administration may be headed for a second straight year of cuts to its non-user fee funding, a move that could hamper its ability to handle increasing salary obligations, complete a major reorganization, and adapt to expensive new technology like artificial intelligence.
Key Takeaways
-
The House subcommittee bill would cut the FDA's non-user fee funding for the second consecutive year.
The House Appropriations Agriculture, Rural Development and FDA Subcommittee advanced a fiscal year 2025 funding bill via voice vote...







